HopeStage
Back to all studies
CompletedNCT00318448

Zolpidem for insomnia in children with ADHD

About this titleRead the official source — NCT00318448
Medication studyAges 6–17United States + Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 6 years to 17 years.

Listed locations
Bridgewater and 1 more locationSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateApril 2006
Recruitment status
Completed
Enrollment listed in the registry
201
Sponsor
Sanofi
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada
Age range
From 6 Years to 17 Years
Official registry ID
NCT00318448
Official title
Show the full official title

Efficacy, Safety and Tolerability of Zolpidem in the Treatment of Children Aged 6 to 17 Years With ADHD-Associated Insomnia. A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bridgewater, United States · Laval, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Sanofi.

Did this study involve medication?

Yes. The study involved medication, including Zolpidem (SL800750).

Who was this study for?

Listed age limits: 6 years to 17 years.

Want to explore more studies?

Explore studies